Development and validation of a multiplex add-on assay for sepsis biomarkers using xMAP technology

Kristian Kofoed; Uffe Vest Schneider; Troels Scheel; Ove Andersen; Jesper Eugen-Olsen

doi:10.1373/clinchem.2006.067595

Development and validation of a multiplex add-on assay for sepsis biomarkers using xMAP technology

Kristian Kofoed, Uffe Vest Schneider, Troels Scheel, Ove Andersen, Jesper Eugen-Olsen

Department of Clinical Medicine

103 Citations (Scopus)

Abstract

BACKGROUND: Sepsis is a common and often fatal disease. Because sepsis can be caused by many different organisms, biomarkers that can aid in diagnosing sepsis and monitoring treatment efficacy are highly warranted. New sepsis markers may provide additional information to complement the currently used markers.

METHODS: We used a combination of in-house and commercially available multiplex immunoassays based on Luminex xMAP technology to assay biomarkers of potential interest in EDTA-plasma samples.

RESULTS: A 3-plex assay for soluble urokinase plasminogen activator receptor (suPAR), soluble triggering receptor expressed on myeloid cells-1 (sTREM-1), and macrophage migration inhibiting factor (MIF) was developed and validated in-house. This 3-plex assay was added to a commercially available interleukin-1beta (IL-1beta), IL-6, IL-8, granulocyte/macrophage colony-stimulating factor, and tumor necrosis factor-alpha human cytokine panel. No cross-reactivity was observed when the assays were combined. Correlation between values obtained with the 8-plex, the 5-cytokine panel, the 3 in-house 1-plex assays, and a suPAR ELISA ranged from 0.86 to 0.99. Mean within- and between-run CVs were 8.0% and 11%, respectively. Recoveries of suPAR, sTREM-1, and MIF calibrators were 108%, 88%, and 51%, respectively. In plasma collected from 10 patients with bacterial sepsis confirmed by blood culture, the assay detected significantly increased concentrations of all 8 analytes compared with healthy controls.

CONCLUSIONS: A commercially available xMAP panel can be expanded with markers of interest. The combined multiplex assay can measure the 8 analytes with high reproducibility. The xMAP technology is an appealing tool for assaying conventional cytokines in combination with new markers.

Original language	English
Journal	Clinical Chemistry
Volume	52
Issue number	7
Pages (from-to)	1284-93
Number of pages	10
ISSN	0009-9147
DOIs	https://doi.org/10.1373/clinchem.2006.067595
Publication status	Published - Jul 2006

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1373/clinchem.2006.067595

Cite this

@article{c425b4d565384448b62c9ae10c6904f5,

title = "Development and validation of a multiplex add-on assay for sepsis biomarkers using xMAP technology",

abstract = "BACKGROUND: Sepsis is a common and often fatal disease. Because sepsis can be caused by many different organisms, biomarkers that can aid in diagnosing sepsis and monitoring treatment efficacy are highly warranted. New sepsis markers may provide additional information to complement the currently used markers.METHODS: We used a combination of in-house and commercially available multiplex immunoassays based on Luminex xMAP technology to assay biomarkers of potential interest in EDTA-plasma samples.RESULTS: A 3-plex assay for soluble urokinase plasminogen activator receptor (suPAR), soluble triggering receptor expressed on myeloid cells-1 (sTREM-1), and macrophage migration inhibiting factor (MIF) was developed and validated in-house. This 3-plex assay was added to a commercially available interleukin-1beta (IL-1beta), IL-6, IL-8, granulocyte/macrophage colony-stimulating factor, and tumor necrosis factor-alpha human cytokine panel. No cross-reactivity was observed when the assays were combined. Correlation between values obtained with the 8-plex, the 5-cytokine panel, the 3 in-house 1-plex assays, and a suPAR ELISA ranged from 0.86 to 0.99. Mean within- and between-run CVs were 8.0% and 11%, respectively. Recoveries of suPAR, sTREM-1, and MIF calibrators were 108%, 88%, and 51%, respectively. In plasma collected from 10 patients with bacterial sepsis confirmed by blood culture, the assay detected significantly increased concentrations of all 8 analytes compared with healthy controls.CONCLUSIONS: A commercially available xMAP panel can be expanded with markers of interest. The combined multiplex assay can measure the 8 analytes with high reproducibility. The xMAP technology is an appealing tool for assaying conventional cytokines in combination with new markers.",

keywords = "Biological Markers, Chemotactic Factors, Cross Reactions, Granulocyte-Macrophage Colony-Stimulating Factor, Humans, Immunoassay, Interleukin-1, Interleukin-6, Interleukin-8, Macrophages, Membrane Glycoproteins, Receptors, Cell Surface, Receptors, Immunologic, Receptors, Urokinase Plasminogen Activator, Sepsis, Tumor Necrosis Factor-alpha",

author = "Kristian Kofoed and Schneider, {Uffe Vest} and Troels Scheel and Ove Andersen and Jesper Eugen-Olsen",

year = "2006",

month = jul,

doi = "10.1373/clinchem.2006.067595",

language = "English",

volume = "52",

pages = "1284--93",

journal = "Clinical Chemistry",

issn = "0009-9147",

publisher = "American Association for Clinical Chemistry, Inc.",

number = "7",

}

TY - JOUR

T1 - Development and validation of a multiplex add-on assay for sepsis biomarkers using xMAP technology

AU - Kofoed, Kristian

AU - Schneider, Uffe Vest

AU - Scheel, Troels

AU - Andersen, Ove

AU - Eugen-Olsen, Jesper

PY - 2006/7

Y1 - 2006/7

N2 - BACKGROUND: Sepsis is a common and often fatal disease. Because sepsis can be caused by many different organisms, biomarkers that can aid in diagnosing sepsis and monitoring treatment efficacy are highly warranted. New sepsis markers may provide additional information to complement the currently used markers.METHODS: We used a combination of in-house and commercially available multiplex immunoassays based on Luminex xMAP technology to assay biomarkers of potential interest in EDTA-plasma samples.RESULTS: A 3-plex assay for soluble urokinase plasminogen activator receptor (suPAR), soluble triggering receptor expressed on myeloid cells-1 (sTREM-1), and macrophage migration inhibiting factor (MIF) was developed and validated in-house. This 3-plex assay was added to a commercially available interleukin-1beta (IL-1beta), IL-6, IL-8, granulocyte/macrophage colony-stimulating factor, and tumor necrosis factor-alpha human cytokine panel. No cross-reactivity was observed when the assays were combined. Correlation between values obtained with the 8-plex, the 5-cytokine panel, the 3 in-house 1-plex assays, and a suPAR ELISA ranged from 0.86 to 0.99. Mean within- and between-run CVs were 8.0% and 11%, respectively. Recoveries of suPAR, sTREM-1, and MIF calibrators were 108%, 88%, and 51%, respectively. In plasma collected from 10 patients with bacterial sepsis confirmed by blood culture, the assay detected significantly increased concentrations of all 8 analytes compared with healthy controls.CONCLUSIONS: A commercially available xMAP panel can be expanded with markers of interest. The combined multiplex assay can measure the 8 analytes with high reproducibility. The xMAP technology is an appealing tool for assaying conventional cytokines in combination with new markers.

AB - BACKGROUND: Sepsis is a common and often fatal disease. Because sepsis can be caused by many different organisms, biomarkers that can aid in diagnosing sepsis and monitoring treatment efficacy are highly warranted. New sepsis markers may provide additional information to complement the currently used markers.METHODS: We used a combination of in-house and commercially available multiplex immunoassays based on Luminex xMAP technology to assay biomarkers of potential interest in EDTA-plasma samples.RESULTS: A 3-plex assay for soluble urokinase plasminogen activator receptor (suPAR), soluble triggering receptor expressed on myeloid cells-1 (sTREM-1), and macrophage migration inhibiting factor (MIF) was developed and validated in-house. This 3-plex assay was added to a commercially available interleukin-1beta (IL-1beta), IL-6, IL-8, granulocyte/macrophage colony-stimulating factor, and tumor necrosis factor-alpha human cytokine panel. No cross-reactivity was observed when the assays were combined. Correlation between values obtained with the 8-plex, the 5-cytokine panel, the 3 in-house 1-plex assays, and a suPAR ELISA ranged from 0.86 to 0.99. Mean within- and between-run CVs were 8.0% and 11%, respectively. Recoveries of suPAR, sTREM-1, and MIF calibrators were 108%, 88%, and 51%, respectively. In plasma collected from 10 patients with bacterial sepsis confirmed by blood culture, the assay detected significantly increased concentrations of all 8 analytes compared with healthy controls.CONCLUSIONS: A commercially available xMAP panel can be expanded with markers of interest. The combined multiplex assay can measure the 8 analytes with high reproducibility. The xMAP technology is an appealing tool for assaying conventional cytokines in combination with new markers.

KW - Biological Markers

KW - Chemotactic Factors

KW - Cross Reactions

KW - Granulocyte-Macrophage Colony-Stimulating Factor

KW - Humans

KW - Immunoassay

KW - Interleukin-1

KW - Interleukin-6

KW - Interleukin-8

KW - Macrophages

KW - Membrane Glycoproteins

KW - Receptors, Cell Surface

KW - Receptors, Immunologic

KW - Receptors, Urokinase Plasminogen Activator

KW - Sepsis

KW - Tumor Necrosis Factor-alpha

U2 - 10.1373/clinchem.2006.067595

DO - 10.1373/clinchem.2006.067595

M3 - Journal article

C2 - 16690735

SN - 0009-9147

VL - 52

SP - 1284

EP - 1293

JO - Clinical Chemistry

JF - Clinical Chemistry

IS - 7

ER -

Development and validation of a multiplex add-on assay for sepsis biomarkers using xMAP technology

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this